Sharp Therapeutics Corp. (TSXV:SHRX)

Sharp Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022
Cash & Equivalents	0.23	0.38	0.16
Cash & Short-Term Investments	0.23	0.38	0.16
Cash Growth	-	129.45%	-
Prepaid Expenses	0.04	0.05	0.03
Total Current Assets	0.3	0.43	0.2
Property, Plant & Equipment	1.07	1.1	1.21
Other Long-Term Assets	0.02	0.02	0.02
Total Assets	1.39	1.55	1.42
Accounts Payable	0.43	0.18	0.1
Accrued Expenses	0.43	0.23	0.13
Current Portion of Long-Term Debt	-	7.28	3.94
Current Portion of Leases	0.03	0.03	0.03
Total Current Liabilities	14.6	7.72	4.2
Long-Term Debt	-	3.97	3.8
Long-Term Leases	1.3	1.32	1.34
Other Long-Term Liabilities	-	0.02	0.02
Total Liabilities	15.9	13.03	9.37
Common Stock	4.55	4.55	4.55
Additional Paid-In Capital	0.6	0.59	0.56
Retained Earnings	-19.66	-16.62	-13.06
Shareholders' Equity	-14.51	-11.48	-7.95
Total Liabilities & Equity	1.39	1.55	1.42
Total Debt	15.03	12.6	9.11
Net Cash (Debt)	-14.79	-12.22	-8.95
Net Cash Per Share	-106.22	-87.82	-64.45
Filing Date Shares Outstanding	1.39	1.39	0.14
Total Common Shares Outstanding	1.39	1.39	0.14
Working Capital	-14.3	-7.29	-4.01
Book Value Per Share	-10.42	-8.25	-57.25
Tangible Book Value	-14.51	-11.48	-7.95
Tangible Book Value Per Share	-10.42	-8.25	-57.25
Machinery	0.21	0.2	0.18

Source: S&P Global Market Intelligence. Standard template. Financial Sources.